Dose selection of adjuvanted synthetic nanocarriers

Abstract

Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.

1 . A method comprising:
 providing a dose of adjuvant and a dose of antigen, wherein at least a portion of the dose of adjuvant is coupled to synthetic nanocarriers,   generating an antibody titer against the antigen through administration of the dose of adjuvant and the dose of antigen to a subject, and   choosing the dose of adjuvant to be less than a separate dose of adjuvant that results in an antibody titer similar to that generated through administration of the dose of adjuvant and the dose of antigen to the subject.   
     
     
         2 .- 16 . (canceled) 
     
     
         17 . The method of  claim 1 , wherein the synthetic nanocarriers comprise one or more polymers. 
     
     
         18 . (canceled) 
     
     
         19 . The method of  claim 17 , wherein the one or more polymers comprise or further comprise a polyester coupled to a hydrophilic polymer. 
     
     
         20 . (canceled) 
     
     
         21 . The method of  claim 19 , wherein the hydrophilic polymer comprises a polyether. 
     
     
         22 . (canceled) 
     
     
         23 .- 25 . (canceled) 
     
     
         26 . The method of  claim 1 , wherein the subject has cancer, an infectious disease, a non-autoimmune metabolic disease, a degenerative disease, an addiction, and atopic condition, asthma; chronic obstructive pulmonary disease (COPD) or a chronic infection. 
     
     
         27 . (canceled) 
     
     
         28 . A method comprising:
 providing a dose of adjuvant, wherein at least a portion of the dose of adjuvant is coupled to synthetic nanocarriers,   generating a systemic cytokine release through administration of the dose of adjuvant to a subject, and   choosing the dose of adjuvant to be greater than a separate dose of adjuvant that results in a systemic cytokine release similar to that generated through administration of the dose of adjuvant to the subject.   
     
     
         29 . The method of  claim 28 , wherein the adjuvant comprises an agonist for Toll-Like Receptors 3, 4, 5, 7, 8, or 9 or a combination thereof. 
     
     
         30 .- 31 . (canceled) 
     
     
         32 . The method of  claim 28 , wherein the dose of adjuvant comprises two or more types of adjuvants. 
     
     
         33 . The method of  claim 28 , wherein a portion of the dose of adjuvant is not coupled to the synthetic nanocarriers. 
     
     
         34 . The method of  claim 28 , wherein more than one type of antigen are administered to the subject. 
     
     
         35 . The method of  claim 34 , wherein at least a portion of a dose of antigen(s) is coupled to the synthetic nanocarriers. 
     
     
         36 . The method of  claim 34 , wherein at least a portion of a dose of antigen(s) is not coupled to the synthetic nanocarriers. 
     
     
         37 . The method of  claim 34 , wherein at least a portion of a dose of antigen(s) is coadministered with the synthetic nanocarriers. 
     
     
         38 . The method of  claim 34 , wherein at least a portion of a dose of antigen(s) is not coadministered with the synthetic nanocarriers. 
     
     
         39 .- 41 . (cancelled) 
     
     
         42 . The method of  claim 28 , wherein the administration is by a route that comprises subcutaneous, intramuscular, intradermal, oral, intranasal, transmucosal, rectal; ophthalmic, transdermal or transcutaneous administration, or a combination thereof. 
     
     
         43 . The method of  claim 28 , wherein the synthetic nanocarriers comprise lipid nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles, peptide or protein particles, nanoparticles that comprise a combination of nanomaterials, spheroidal nanoparticles, cuboidal nanoparticles, pyramidal nanoparticles, oblong nanoparticles, cylindrical nanoparticles, or toroidal nanoparticles. 
     
     
         44 . The method of  claim 28 , wherein the synthetic nanocarriers comprise one or more polymers. 
     
     
         45 . The method of  claim 44 , wherein the one or more polymers comprise a polyester. 
     
     
         46 .- 52 . (canceled) 
     
     
         53 . The method of  claim 28 , wherein the subject has cancer, an infectious disease, a non-autoimmune metabolic disease, a degenerative disease, an addiction, and atopic condition, asthma; chronic obstructive pulmonary disease (COPD) or a chronic infection. 
     
     
         54 .- 59 . (canceled) 
     
     
         60 . A dose of adjuvant and dose of antigen as defined in  claim 1 , for use in therapy or prophylaxis. 
     
     
         61 .- 64 . (canceled)